Not for distribution by US newswire or in
NESS-ZIONA,
As recently reported, Vaxil is making progress in the licensed drug delivery polymer that targets, with high affinity, E-selectin (P-Esbp), which was invented by Prof.
In order to further explore and establish the potential of P-Esbp-DOX for treating metastic cancer, an in-vivo experiment was designed aimed at evaluating the therapeutic efficacy of P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal tumors. To this end, P-Esbp was successfully conjugated with DOX, and the maximum tolerated dose of P-Esbp-DOX was determined in the suitable mouse strain. Preliminary results of this experiment demonstrates at day 45, 70% of animals (5/7) treated with a single dose of P-Esbp-DOX-FITC at day 4 post tumor implantation remain alive and 40% (3/7) appear tumor free. This is compared to 1/6 and 0/6 animals alive in the alternate treatment and control arms.
A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6d473cdd-5542-4a4e-a776-f30bc192e974
Vaxil is completing the final report including in vivo imaging in the coming month and will share the data when complete.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The Company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Neither
Disclaimer: The Company cautions that
CONTACT INFORMATION
For further information please visit https://vaxil-bio.com/ or contact:
Figure 1
In vivo mice survival in experimental CRC liver metastasis model
2021 GlobeNewswire, Inc., source